Equities

Bide Pharmatech Co Ltd

688073:SHH

Bide Pharmatech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)29.44
  • Today's Change-0.48 / -1.60%
  • Shares traded345.29k
  • 1 Year change-50.63%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2731,505193
Total Receivables, Net269201142
Total Inventory699522477
Prepaid expenses18126.16
Other current assets, total0.865.290.10
Total current assets2,2612,245818
Property, plant & equipment, net979463
Goodwill, net------
Intangibles, net0.600.210.44
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets2,4152,359906
LIABILITIES
Accounts payable180167206
Accrued expenses393220
Notes payable/short-term debt0.239.610.07
Current portion long-term debt/capital leases16----
Other current liabilities, total404023
Total current liabilities275249250
Total long term debt413128
Total debt574128
Deferred income tax8.062.77--
Minority interest------
Other liabilities, total1.27----
Total liabilities325283277
SHAREHOLDERS EQUITY
Common stock916549
Additional paid-in capital1,7541,776483
Retained earnings (accumulated deficit)25224297
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(6.96)(7.25)0.43
Total equity2,0902,076629
Total liabilities & shareholders' equity2,4152,359906
Total common shares outstanding919191
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.